Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Session 10: Approaches to Treatment of Methamphetamine Use Disorder (2 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about approaches to treatment of methamphetamine use disorder, from this conference recording from The ASAM State of the Art Conference, 2018.

    In Session 10, you will learn that methamphetamine use has resurged recently, increasing the need for effective treatment. Behavioral and pharmacological approaches to treatment have been assessed by preclinical and clinical researchers. This session will point out promising preclinical candidates, clinical trials with bupropion and naltrexone, and behavioral therapies with known efficacy. Jane B. Acri, PhD, Richard A. Rawson, PhD, and Frank J. Vocci, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: Compounds and Mechanisms Evaluated Preclinically as Potential Therapeutics for Methamphetamine Disorders, Behavioral/Psychosocial Treatments for Methamphetamine Dependence: Recent Advances and Medication Development for Treatment of Methamphetamine Use Disorder.

  • Session 2: Cocaine: How the Cellular Basis of its Impact Tells the Story (2 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about cocaine and how the cellular basis of its impact tells the story, from this conference recording from The ASAM State of the Art Conference, 2018.

    In session 2, you will learn that cocaine is not just for the 80’s stock broker anymore! The subcellular pharmacokinetics make this a particularly difficult substance to treat. We will walk through the advanced neuroscience, the animal models that define our predictive understanding, and the behavioral aspects of both the pathology and treatment. While opioids have captured recent headlines, cocaine and its close cousin methamphetamine have been smoldering in the background. Although we do not have medications with good evidence for treatment, we can predict the withdrawal syndrome and the behaviors that drive utilization. With this knowledge we can build better interventions that are both helpful and reimbursed. 
  • Session 5: Breaking Down Barriers that Block Quality Care (2.25 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 2.25 AMA PRA Category 1 Credit(s)™ while learning more about breaking down barriers that block quality care, from this conference recording from The ASAM State of the Art Conference, 2018.

    In Session 5, you will wonder why you are even watching this session. I mean, we have access to treatment on demand, everyone knows the evidence, there is ample funding for treatment, and thank goodness that everyone screens for addiction in their practice. Maybe we would need this session if there was stigma, but everyone agrees that addiction is a chronic brain disorder and are competing for treatment centers to open in their neighborhoods. Really, thank goodness that medical schools and residency programs spend a lot of time training new physicians for the complexity of this disease and how to treat it. Because of this, we have a vibrant, motivated workforce just waiting for the next addiction patient. So, I am not sure what we are going to discuss, but it would be great if we had an audience for our speakers. Anthony Campbell, RPH, DO, CDR, USPHS, R. Corey Waller, MD, MS, FACEP, DFASAM, and Chideha M. Ohouha MD, MPHbring their years of experience and expertise to deliver an exceptional presentation covering the following: The Federal Policy Response to Removing Barriers, If Getting into the US Was Like Getting into Addiction Treatment We Wouldn't Need a Wall, Buprenorphine Prescribing: Getting to Yes, and Audience Discussion with Panelists.

  • Session 9: Overdose, Self-Harm, Suicide, and the Gray Areas in Between (1.5 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning more about overdose, self-harm, suicide, and other gray areas in between, from this conference recording from The ASAM State of the Art Conference, 2018.

    During Session 9 you will learn that suicides and fatal drug overdoses are increasing in the US. Moreover, deaths involving drug intoxication are likely underreported, suggesting the problem is worse than the current statistics show. The contribution of the current opioid epidemic to the escalating deaths from overdose will be highlighted and opioid-specific prevention strategies will be discussed. The continuum of self-harm will be considered from both a risk factor and developmental point of view. Assessment of suicide risk and potential intervention strategies to de-escalate risk will be explored. Richard K. Ries, MD, FAPA, DFASAM, Hilary S. Connery, MD, PhD, and Richard K. Ries, MD, FAPA, DFASAMbring their years of experience and expertise to deliver an exceptional presentation covering the following: Overdose Suicide and the Gray Areas in Between, Diagnosis Prevalence and Interventions of Self-Harm in Addiction Patient Populations, and Suicide Screening and Intervention in Individuals with Substance Use Disorders..

  • Session 1: The Opioid Crisis: Current Status and Treatment Responses (2.25 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 2.25 AMA PRA Category 1 Credit(s)™ while learning more about the current status and treatment responses to address the opioid crisis, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 1 examines several topics in the field of opioid-related morbidity and mortality, as well as the treatment of opioid use disorder. Presenters will dive into updates on opioid misuse, overdose epidemiology, and current national trends. This will be followed by an updated review of evidence-based strategies for opioid overdose prevention, and an overview of data that are the basis of current approaches for the investigation of novel kappa-opioid receptor ligands for the treatment of opioid use disorder. Finally, we will close with a review of recent clinical trials examining the efficacy and effectiveness of extended-release (XR) medications for the treatment of opioid use disorder. Richard C. Dart, MD, PhD, Alexander Y. Walley, MD, MSc, FSAM, Eduardo R. Butelman, PhD, and Joshua D. Lee, MD, MSc bring their years of experience and expertise to deliver an exceptional presentation covering the following: Opioid Epidemiology in the Age of Fentanyl, Opioid Overdose Prevention and Management in a Dynamic Opioid Crisis, Targeting the Kappa-Opioid Receptor System for Developing New Pharmacotherapies for Opioid Use Disorder, and Long-Acting Naltrexone and Buprenorphine Formulations: Efficacy Effectiveness and Comparative Effectiveness.

  • Addressing Emerging Issues and Advances in Addiction Medicine Fire Side Chat (1 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about emerging issues and advances in addiction medicine, from this conference recording from The ASAM State of the Art Conference, 2018.

    During this informal Fireside Chat from The ASAM State of the Art Conference in 2018, federal agency representatives, agency leaders will each give a five-minute overview from their respective organizations about emerging issues and advances in addiction medicine, increasing the addiction medicine workforce, and improving the quality of care for patients. Dr. Clark will engage each representative in a lively conversation with George F. Koob, PhD, Wilson M. Compton, MD, MPE, Anita Everett, MD, and Janet Woodcock, MDbring their years of experience and expertise to deliver an exceptional presentation covering the following: emerging issues and advances in addiction medicine .

  • Session 4: Cannabis and Coexisting Disorders (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning more about cannabis and coexisting disorders, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 4 examines several topics in the field of cannabinoids, cannaboid use, and coexisting disorders. As a continuation of cannabis topics, this session will continue with a presentation on advances in pharmacotherapies for cannabis use disorders, the impact and effect of marijuana use on treating other substance use disorders, consequences of expanded marijuana use on opioid usage, and the CBD products. Kevin M. Gray, MD, Dustin C. Lee, PhD, and Rosalie L. Pacula, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: Advances with Pharmacotherapies for Cannabis Use Disorder, Impact of Marijuana Use on Treating Other Substance Use Disorders, and The Public Health Impacts of Expanded Cannabis Access.

  • Session 7: Substance Use in Adolescents and Young Adults (1 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about substance use in adolescents and young adults, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 7 covers problematic substance use and binge drinking often begin in adolescence and young adulthood. Treatments for opioid use disorder are developed in adult populations. Whether the efficacy of opioid use disorder treatments seen in adults translates to similar efficacy in adolescent populations is an empirical question that will be explored. Binge drinking in adolescents and young adults occurs at a time of enhanced neural plasticity and may affect the trajectory of brain development. The effects of binge drinking on brain systems will bediscussed and potential approaches to prevent binge drinking will be highlighted. Wilson M. Compton, MD, MPE and George F. Koob, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: Opioid Use Disorder in Adolescents and Young Adults and Prevention of Adolescent Binge Drinking: A Neurodevelopmental View.

  • Session 6: Alcohol and Opioid Use in Women and Girls: Health Impacts and Treatment (2 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about alcohol and opioid use in women and girls, from this conference recording from The ASAM State of the Art Conference, 2018.

    In session 6, you will learn that drinking too much alcohol can seriously affect the health of women and girls. Excessive alcohol use increases the risk of certain types of cancers, heart disease, sexually transmitted diseases, unintended pregnancy, and many other health problems. This session will highlight findings from current research on drinking among women and girls. Deborah S. Hasin, PhD, George F. Koob, PhD, Rajita Sinha, PhD, Grace Chang, MD, MPH, Constance M. Weisner, DrPH, LCSW and Mary E. McCaul, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: US Trends in Harmful Substance Use Among Women and Girls, Alcohol and the Female Brain, Harmful Effects of Alcohol and Opioid Use in Women and Girls, Health Impacts of Maternal Alcohol Use, Implementation and Outcomes of Screening and Brief Intervention for Women in Primary Care, and Do Women Benefit from Specialty Treatment for Alcohol and Drug Use Disorders?.

  • Webinar: What is Multidimensional Assessment: Matching Services to Needs and Strengths

    Contains 1 Component(s) Recorded On: 11/09/2018

    In this free webinar, learn more about multi-dimensional assessment, level of care placement decisions found in the ASAM Criteria, with a focus on criminal justice settings.​

    Webinar Overview

    Join Dr. David Mee-Lee, leading expert in substance use disorder treatment and Chief Editor of The ASAM Criteria®, for an informative webinar that will explain state of the art addiction assessment and treatment. The webinar will describe the multi-dimensional assessment and level of care placement decisions found in The ASAM Criteria, with a focus on criminal justice settings. This webinar, which is jointly sponsored by the National Association of Drug Court Professionals and the American Society of Addiction Medicine, is designed especially for counselors, social workers, therapists, case managers, and others who provide drug treatment services in drug courts.

    Learning Objectives

    After watching this webinar, participants will be able to:

    1. Discuss attitudes about substance use, the definition of addiction, and the role of multidimensional assessments in state-of-the-art addiction treatment.
    2. Review characteristics of state-of-the-art addiction treatment, the guiding principles of The ASAM Criteria, and their applications in criminal justice settings.
    3. Apply The ASAM Criteria multidimensional assessment to individualize treatment and move courts from program-driven treatment to a continuum of outcomes-driven services that improves participant outcomes.
    4. Discuss how to achieve accountable change in drug court participants through the common language of The ASAM Criteria and a focus on “doing treatment and change” not “doing time”.

    David Mee-Lee

    MD, FASAM

    David Mee-Lee, M.D. is a board-certified psychiatrist, and is certified by the American Board of Addiction Medicine (ABAM). Based in Davis, California, he trains and consults both nationally and internationally.  Dr. Mee-Lee is Chief Editor of the American Society of Addiction Medicine's (ASAM) Criteria for the Treatment of Addictive, Substance-Related, and Co-Occurring Conditions and is President of DML Training and Consulting. He is co-founder of the Institute for Wellness Education. Dr. Mee-Lee has forty years of experience in person centered treatment and program development for people with co-occurring mental health and substance use conditions.